Information Provided By:
Fly News Breaks for May 24, 2016
FCSC
May 24, 2016 | 08:56 EDT
Roth Capital analyst Matt Koranda resumed coverage of Fibrocell Science with a Buy rating and $7 price target. The analyst says the company is using the inherent properties of fibroblasts for therapeutic use and is also looking to leverage gene therapy to engineer these fibroblasts to treat both monogenic diseases as well as broader indications. Additionally, Fibrocell has the potential to treat the devastating disease of RDEB, Koranda tells investors in a research note.
News For FCSC From the Last 2 Days
There are no results for your query FCSC
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.